http://www.labce.com/advance-landing.aspx

Free Subscription & E-newsletter


Daily News Update

Roche 454 Sequencing Systems Resolve Genetic Mutations in Over 4,000 Blood Cancer Cases

Posted on: December 21, 2012
Print ArticleEmail Article
Share
reddit Newsvine Del.icio.us Digg
Yahoo! Buzz LinkedIn StumbleUpon Google Bookmarks Mixx
At the American Society of Hematology Meeting (ASH) earlier this month, Roche announced the presentation of results from the large scale study IRON-II through an international research consortium. Based on next generation 454 Sequencing Systems from Roche, the study aims to characterize selected genes in individuals with a wide range of hematological malignancies. The consortium of 26 laboratories from 13 countries in Europe and Asia performed comprehensive analysis of 74 genes in individuals with acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphatic leukemia, chronic
myelogenous leukemia, myelodysplastic syndromes and myeloproliferative neoplasms.

The results from over 4,000 cases demonstrate that the highly advanced technology supports the comprehensive molecular characterization of hematological malignancies with high sensitivity and specificity, with the future prospect of guiding more personalized treatment decisions. The study is one of dozens of abstracts and talks using 454 Sequencing Systems presented at the ASH meeting

Researchers from the MLL Munich Leukemia (MLL) Laboratory, pioneering the adoption of next-generation sequencing to profile blood cancers, are leading the international consortium. Earlier this year, Roche launched a set of sequence-based primer sets co-developed with the MLL for deep genetic variation detection in the TET2, CBL, KRAS, and RUNX1 genes using the GS FLX and GS Junior Systems. The current study is an extension of the previous IRON study which demonstrated the robustness, precision and reproducibility of next generation sequencing with 454 Sequencing Systems for characterization of key genes associated with leukemia. It broadens the set of genes from 3 to 74 with a new expanded set of investigative primer plates.   

"We are particularly pleased with the performance of the Roche assays in combination with the high quality long read length of the 454 Sequencing Systems. This is the only technology that allows us to resolve complex variations in genes such as RUNX1 or CEBPA and enables us to address questions such as landmark analyses in various mutated genes in hematological  malignancies and the development of future prognostic models," said Dr. Alexander Kohlmann, head of the Next Generation Sequencing Group at the MLL and coauthor of 28 studies presented at this year's conference. "One key aspect of the IRON-II study is that we now achieved to standardize gene content via amplicon-based deep-sequencing assays across hematological expert laboratories, including the bioinformatic analysis approaches."



   

News Watch Archives


View the Latest from ADVANCE

 
 

Search Jobs

Go
 
 

Search Articles

Search our archives for print and web articles.

Go >
 
http://laboratory-manager.advanceweb.com/webinar/webinar.aspx?rid=548

Professions

Get Involved

Resources

Corporate


© 2013 Merion Matters 2900 Horizon Drive King of Prussia PA 19406 800-355-5627